Premium
Evolving role of surgical treatment in limited‐disease small cell lung carcinoma
Author(s) -
Sridhar Kasi S.,
Hussein Atif M.,
Thurer Richard J.
Publication year - 1989
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.2930400305
Subject(s) - medicine , chemotherapy , carcinoma , lung , small cell carcinoma , small cell lung carcinoma , curative treatment , surgical resection , oncology , surgery , disease , adjuvant , adjuvant chemotherapy , cancer , breast cancer
The diagnostic role of surgical procedures in small cell lung carcinoma (SCLC) is well established. The therapeutic role of surgery has changed over the years. At present, curative resection is the treatment of choice in peripheral T 1‐2 N o M o SCLC, and adjuvant chemotherapy may be beneficial. Surgery is also indicated in SCLC patients diagnosed by a limited pathologic sample in whom the clinical course suggests nonsmall cell lung carcinoma (NSCLC). The resection may reveal either a mixed tumor or an alternate diagnosis and may be potentially curative. Surgery, at the time of maximal response to chemotherapy in T 3 N o M o SCLC, may be curative and reveal the presence of NSCLC elements. The best survival is in patients found to be tumor‐free at surgery, and the worst survival is in N 2 patients.